YWP
LRMR icon

YorkBridge Wealth Partners’s Larimar Therapeutics LRMR Stock Holding History

YorkBridge Wealth Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21
Closed – – 453
2019
Q2 		$0 Hold
21
– – ﹤0.01% 760
2019
Q1 		$1K Hold
21
– – ﹤0.01% 727
2018
Q4 		$1K Sell
21
-21
-50% -$2.07K ﹤0.01% 710
2018
Q3 		$6K Hold
42
– – ﹤0.01% 643
2018
Q2 		$5K Hold
42
– – ﹤0.01% 686
2018
Q1 		$4K Hold
42
– – ﹤0.01% 698
2017
Q4 		$4K Hold
42
– – ﹤0.01% 728
2017
Q3 		$2K Hold
42
– – ﹤0.01% 791
2017
Q2 		$2K Buy
+42
New +$2.15K ﹤0.01% 786

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

YorkBridge Wealth Partners's LRMR Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 21 shares.

YorkBridge Wealth Partners first reported a position in LRMR in Q2 2017 and held it in 9 quarters. The position peaked at $6K in Q3 2018. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

  • YorkBridge Wealth Partners reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • YorkBridge Wealth Partners sold 21 Larimar Therapeutics shares in Q3 2019.
  • YorkBridge Wealth Partners first reported a position in Larimar Therapeutics in Q2 2017 and held it in 9 quarters.
  • YorkBridge Wealth Partners's Larimar Therapeutics position peaked at $6K in Q3 2018.
  • 51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.